At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate PFE stock a Sell.

5. Still paying a great dividend I'm confident that Pfizer will still pay a great dividend in 2030. The company's management remains firmly committed to the dividend program.

Pfizer's strong EPS surprise streak and positive earnings revisions are encouraging, but patent cliff risks remain a major concern for future growth.

2. Pfizer Pfizer (PFE 0.32%) is the most well-known of the high-paying healthcare dividend stocks on this list. The company was founded in 1849.

One of the most appealing features of Pfizer's stock is its dividend. The payout recently yielded a hefty 7.4% -- and it's been growing over time. There's reason to be bullish over Pfizer's long ...

Senator Ron Wyden (D-Oregon) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on July 02nd, the Senator disclosed that they had sold between $1,001 and $15,000 in Pfizer stock ...

Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P 500 index fund. Still, Pfizer today offers a fat dividend and plenty ...

The stock's low valuation and ultra-high dividend make it a good choice for long-term investors. 10 stocks we like better than Pfizer › ...

Finally, Pfizer is a dividend-paying stock, with a whopping recent dividend yield of 7%. So as you invest in Pfizer and wait for its investments to pay off, you'll be rewarded.

Pfizer's beleaguered obesity strategy has hit another setback as the pharma jettisoned its third and final GLP-1 agonist, citing poor data and tough competition. Pfizer's last remaining GLP-1 ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE stock remains undervalued at its present ...

Pfizer PFE is set to give its latest quarterly earnings report on Tuesday, 2025-08-05. Here's what investors need to know before the announcement. Analysts estimate that Pfizer will report an ...